ID   STAT3_HUMAN             Reviewed;         770 AA.
AC   P40763; A8K7B8; K7ENL3; O14916; Q9BW54;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   18-JUN-2025, entry version 250.
DE   RecName: Full=Signal transducer and activator of transcription 3 {ECO:0000305};
DE   AltName: Full=Acute-phase response factor {ECO:0000303|PubMed:7512451};
GN   Name=STAT3 {ECO:0000303|PubMed:9630560, ECO:0000312|HGNC:HGNC:11364};
GN   Synonyms=APRF {ECO:0000303|PubMed:7512451};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TYR-561.
RC   TISSUE=Placenta;
RX   PubMed=7512451; DOI=10.1016/0092-8674(94)90235-6;
RA   Akira S., Nishio Y., Inoue M., Wang X.-J., Wei S., Matsusaka T.,
RA   Yoshida K., Sudo T., Naruto M., Kishimoto T.;
RT   "Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-
RT   related transcription factor involved in the gp130-mediated signaling
RT   pathway.";
RL   Cell 77:63-71(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9630560; DOI=10.1016/s0378-1119(98)00185-1;
RA   Della Pietra L., Bressan A., Pezzotti A., Serlupi-Crescenzi O.;
RT   "Highly conserved amino-acid sequence between murine STAT3 and a revised
RT   human STAT3 sequence.";
RL   Gene 213:119-124(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Feinstein E., Adamsky S., Erlich S., Molitoris B.;
RT   "Methods for treating chronic kidney disease.";
RL   Patent number EP2440214, 18-APR-2012.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-143.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND DEL-701).
RC   TISSUE=Kidney, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 564-704.
RC   TISSUE=Liver;
RA   Della Pietra L., Bressan A., Pezzotti A.R., Serlupi-Crescenzi O.;
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PHOSPHORYLATION AT SERINE RESIDUES.
RX   PubMed=7701321; DOI=10.1126/science.7701321;
RA   Zhang X., Blenis J., Li H.-C., Schindler C., Chen-Kiang S.;
RT   "Requirement of serine phosphorylation for formation of STAT-promoter
RT   complexes.";
RL   Science 267:1990-1994(1995).
RN   [11]
RP   INTERACTION WITH PIAS3.
RX   PubMed=9388184; DOI=10.1126/science.278.5344.1803;
RA   Chung C.D., Liao J., Liu B., Rao X., Jay P., Berta P., Shuai K.;
RT   "Specific inhibition of Stat3 signal transduction by PIAS3.";
RL   Science 278:1803-1805(1997).
RN   [12]
RP   PHOSPHORYLATION BY BMX, INTERACTION WITH BMX, AND FUNCTION.
RX   PubMed=10688651; DOI=10.1128/mcb.20.6.2043-2054.2000;
RA   Tsai Y.T., Su Y.H., Fang S.S., Huang T.N., Qiu Y., Jou Y.S., Shih H.M.,
RA   Kung H.J., Chen R.H.;
RT   "Etk, a Btk family tyrosine kinase, mediates cellular transformation by
RT   linking Src to STAT3 activation.";
RL   Mol. Cell. Biol. 20:2043-2054(2000).
RN   [13]
RP   FUNCTION IN IL6 SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=12359225; DOI=10.1016/s0006-291x(02)02291-x;
RA   Yamamoto T., Sekine Y., Kashima K., Kubota A., Sato N., Aoki N.,
RA   Matsuda T.;
RT   "The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates
RT   interleukin-6-mediated signaling pathway through STAT3 dephosphorylation.";
RL   Biochem. Biophys. Res. Commun. 297:811-817(2002).
RN   [14]
RP   INTERACTION WITH NCOA1.
RX   PubMed=11773079; DOI=10.1074/jbc.m111486200;
RA   Giraud S., Bienvenu F., Avril S., Gascan H., Heery D.M., Coqueret O.;
RT   "Functional interaction of STAT3 transcription factor with the coactivator
RT   NcoA/SRC1a.";
RL   J. Biol. Chem. 277:8004-8011(2002).
RN   [15]
RP   INTERACTION WITH HCV CORE PROTEIN.
RX   PubMed=12208879; DOI=10.1084/jem.20012127;
RA   Yoshida T., Hanada T., Tokuhisa T., Kosai K., Sata M., Kohara M.,
RA   Yoshimura A.;
RT   "Activation of STAT3 by the hepatitis C virus core protein leads to
RT   cellular transformation.";
RL   J. Exp. Med. 196:641-653(2002).
RN   [16]
RP   INTERACTION WITH IL23R.
RX   PubMed=12023369; DOI=10.4049/jimmunol.168.11.5699;
RA   Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J.,
RA   Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J.,
RA   O'Farrell A.-M., McClanahan T.K., Zurawski S., Hannum C., Gorman D.,
RA   Rennick D.M., Kastelein R.A., de Waal Malefyt R., Moore K.W.;
RT   "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1
RT   and a novel cytokine receptor subunit, IL-23R.";
RL   J. Immunol. 168:5699-5708(2002).
RN   [17]
RP   FUNCTION IN EGFR SIGNALING, AND INTERACTION WITH EGFR.
RX   PubMed=12873986;
RA   Shao H., Cheng H.Y., Cook R.G., Tweardy D.J.;
RT   "Identification and characterization of signal transducer and activator of
RT   transcription 3 recruitment sites within the epidermal growth factor
RT   receptor.";
RL   Cancer Res. 63:3923-3930(2003).
RN   [18]
RP   PHOSPHORYLATION AT TYR-705 AND SER-727.
RX   PubMed=12763138; DOI=10.1016/s0301-472x(03)00045-6;
RA   Wierenga A.T., Vogelzang I., Eggen B.J., Vellenga E.;
RT   "Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid
RT   cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway.";
RL   Exp. Hematol. 31:398-405(2003).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH IL31RA.
RX   PubMed=15194700; DOI=10.1074/jbc.m401122200;
RA   Dreuw A., Radtke S., Pflanz S., Lippok B.E., Heinrich P.C., Hermanns H.M.;
RT   "Characterization of the signaling capacities of the novel gp130-like
RT   cytokine receptor.";
RL   J. Biol. Chem. 279:36112-36120(2004).
RN   [20]
RP   PHOSPHORYLATION AT SER-727 BY IRAK1.
RX   PubMed=15465816; DOI=10.1074/jbc.m410369200;
RA   Huang Y., Li T., Sane D.C., Li L.;
RT   "IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced
RT   interleukin-10 gene expression.";
RL   J. Biol. Chem. 279:51697-51703(2004).
RN   [21]
RP   INTERACTION WITH TMF1.
RX   PubMed=15467733; DOI=10.1038/sj.onc.1208149;
RA   Perry E., Tsruya R., Levitsky P., Pomp O., Taller M., Weisberg S.,
RA   Parris W., Kulkarni S., Malovani H., Pawson T., Shpungin S., Nir U.;
RT   "TMF/ARA160 is a BC-box-containing protein that mediates the degradation of
RT   Stat3.";
RL   Oncogene 23:8908-8919(2004).
RN   [22]
RP   INTERACTION WITH PELP1.
RX   PubMed=15994929; DOI=10.1158/0008-5472.can-04-4664;
RA   Manavathi B., Nair S.S., Wang R.-A., Kumar R., Vadlamudi R.K.;
RT   "Proline-, glutamic acid-, and leucine-rich protein-1 is essential in
RT   growth factor regulation of signal transducers and activators of
RT   transcription 3 activation.";
RL   Cancer Res. 65:5571-5577(2005).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, ACETYLATION AT LYS-49 AND LYS-87, AND
RP   MUTAGENESIS OF LYS-49 AND LYS-87.
RX   PubMed=16285960; DOI=10.1053/j.gastro.2005.07.055;
RA   Ray S., Boldogh I., Brasier A.R.;
RT   "STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase
RT   response and required for IL-6 induction of angiotensinogen.";
RL   Gastroenterology 129:1616-1632(2005).
RN   [24]
RP   PHOSPHORYLATION AT SER-727 BY ZIPK/DAPK3, INTERACTION WITH ZIPK/DAPK3, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16219639; DOI=10.1093/intimm/dxh331;
RA   Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y.,
RA   Ishida M., Akira S., Matsuda T.;
RT   "Physical and functional interactions between STAT3 and ZIP kinase.";
RL   Int. Immunol. 17:1543-1552(2005).
RN   [25]
RP   INTERACTION WITH SOCS7.
RX   PubMed=15677474; DOI=10.1074/jbc.m411596200;
RA   Martens N., Uzan G., Wery M., Hooghe R., Hooghe-Peters E.L., Gertler A.;
RT   "Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and
RT   leptin signaling by interacting with STAT5 or STAT3 and attenuating their
RT   nuclear translocation.";
RL   J. Biol. Chem. 280:13817-13823(2005).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-705, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT TYR-704 (ISOFORM DEL-701), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [27]
RP   SUBCELLULAR LOCATION, AND NUCLEAR IMPORT MOTIF.
RX   PubMed=15919823; DOI=10.1073/pnas.0501643102;
RA   Liu L., McBride K.M., Reich N.C.;
RT   "STAT3 nuclear import is independent of tyrosine phosphorylation and
RT   mediated by importin-alpha3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8150-8155(2005).
RN   [28]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, ACETYLATION AT LYS-685, AND
RP   MUTAGENESIS OF LYS-685.
RX   PubMed=15653507; DOI=10.1126/science.1105166;
RA   Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E.;
RT   "Stat3 dimerization regulated by reversible acetylation of a single lysine
RT   residue.";
RL   Science 307:269-273(2005).
RN   [29]
RP   PHOSPHORYLATION AT TYR-705 BY PTK6.
RX   PubMed=16568091; DOI=10.1038/sj.onc.1209501;
RA   Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.;
RT   "Identification of STAT3 as a specific substrate of breast tumor kinase.";
RL   Oncogene 25:4904-4912(2006).
RN   [30]
RP   INTERACTION WITH PRKCE, AND PHOSPHORYLATION AT SER-727.
RX   PubMed=17875724; DOI=10.1158/0008-5472.can-07-1604;
RA   Aziz M.H., Manoharan H.T., Church D.R., Dreckschmidt N.E., Zhong W.,
RA   Oberley T.D., Wilding G., Verma A.K.;
RT   "Protein kinase Cepsilon interacts with signal transducers and activators
RT   of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its
RT   constitutive activation in prostate cancer.";
RL   Cancer Res. 67:8828-8838(2007).
RN   [31]
RP   FUNCTION, PHOSPHORYLATION, AND MUTAGENESIS OF 434-GLU-GLU-435 AND TYR-705.
RX   PubMed=17344214; DOI=10.1074/jbc.m609798200;
RA   Saxena N.K., Vertino P.M., Anania F.A., Sharma D.;
RT   "leptin-induced growth stimulation of breast cancer cells involves
RT   recruitment of histone acetyltransferases and mediator complex to CYCLIN D1
RT   promoter via activation of Stat3.";
RL   J. Biol. Chem. 282:13316-13325(2007).
RN   [32]
RP   INTERACTION WITH CDK9.
RX   PubMed=17956865; DOI=10.1074/jbc.m706458200;
RA   Hou T., Ray S., Brasier A.R.;
RT   "The functional role of an interleukin 6-inducible CDK9.STAT3 complex in
RT   human gamma-fibrinogen gene expression.";
RL   J. Biol. Chem. 282:37091-37102(2007).
RN   [33]
RP   FUNCTION.
RX   PubMed=18242580; DOI=10.1016/j.bbrc.2007.04.004;
RA   Jiang H., Yu J., Guo H., Song H., Chen S.;
RT   "up-regulation of survivin by leptin/STAT3 signaling in MCF-7 cells.";
RL   Biochem. Biophys. Res. Commun. 368:1-5(2008).
RN   [34]
RP   PHOSPHORYLATION AT SER-727 BY DYRK2.
RX   PubMed=18599021; DOI=10.1016/j.bcp.2008.05.021;
RA   Yoshida K.;
RT   "Role for DYRK family kinases on regulation of apoptosis.";
RL   Biochem. Pharmacol. 76:1389-1394(2008).
RN   [35]
RP   IDENTIFICATION IN A COMPLEX WITH LYN AND PAG1.
RX   PubMed=18070987; DOI=10.1182/blood-2007-05-090985;
RA   Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D.,
RA   van Echten-Deckert G., Lindquist J.A., Schraven B., Din N.U., Borisch B.,
RA   Hoessli D.C.;
RT   "Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine
RT   kinase in human B-NHL rafts.";
RL   Blood 111:2310-2320(2008).
RN   [36]
RP   INTERACTION WITH ARL2BP, PHOSPHORYLATION AT SERINE RESIDUES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18234692; DOI=10.1093/intimm/dxm154;
RA   Muromoto R., Sekine Y., Imoto S., Ikeda O., Okayama T., Sato N.,
RA   Matsuda T.;
RT   "BART is essential for nuclear retention of STAT3.";
RL   Int. Immunol. 20:395-403(2008).
RN   [37]
RP   FUNCTION, INTERACTION WITH EP300, ACETYLATION AT LYS-49 AND LYS-87, AND
RP   MUTAGENESIS OF LYS-49 AND LYS-87.
RX   PubMed=18782771; DOI=10.1074/jbc.m805941200;
RA   Hou T., Ray S., Lee C., Brasier A.R.;
RT   "The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by
RT   interacting with the p300 bromodomain.";
RL   J. Biol. Chem. 283:30725-30734(2008).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [41]
RP   INTERACTION WITH FER, AND PHOSPHORYLATION BY FER.
RX   PubMed=19147545; DOI=10.1158/1541-7786.mcr-08-0117;
RA   Zoubeidi A., Rocha J., Zouanat F.Z., Hamel L., Scarlata E., Aprikian A.G.,
RA   Chevalier S.;
RT   "The Fer tyrosine kinase cooperates with interleukin-6 to activate signal
RT   transducer and activator of transcription 3 and promote human prostate
RT   cancer cell growth.";
RL   Mol. Cancer Res. 7:142-155(2009).
RN   [42]
RP   INTERACTION WITH BIRC5/SURVIVIN.
RX   PubMed=20826784; DOI=10.1074/jbc.m110.152777;
RA   Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A.,
RA   Elenitoba-Johnson K.S., Chin Y.E., Altura R.A.;
RT   "Acetylation directs survivin nuclear localization to repress STAT3
RT   oncogenic activity.";
RL   J. Biol. Chem. 285:36129-36137(2010).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [45]
RP   PHOSPHORYLATION AT TYR-705 IN RESPONSE TO KIT SIGNALING, AND
RP   PHOSPHORYLATION AT SER-727.
RX   PubMed=21135090; DOI=10.1074/jbc.m110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [46]
RP   FUNCTION, AND PHOSPHORYLATION AT TYR-705.
RX   PubMed=22306293; DOI=10.1016/j.molcel.2012.01.001;
RA   Gao X., Wang H., Yang J.J., Liu X., Liu Z.R.;
RT   "Pyruvate kinase M2 regulates gene transcription by acting as a protein
RT   kinase.";
RL   Mol. Cell 45:598-609(2012).
RN   [47]
RP   FUNCTION, AND INTERACTION WITH EIF2AK2.
RX   PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013;
RA   Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H.,
RA   Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O.,
RA   Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.;
RT   "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity.";
RL   Mol. Cell 48:667-680(2012).
RN   [48]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-705; THR-714 AND SER-727,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-704 (ISOFORM DEL-701), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [52]
RP   INTERACTION WITH INPP5F, AND MUTAGENESIS OF TYR-705.
RX   PubMed=25476455; DOI=10.1038/srep07330;
RA   Kim H.S., Li A., Ahn S., Song H., Zhang W.;
RT   "Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity
RT   and suppresses gliomas tumorigenicity.";
RL   Sci. Rep. 4:7330-7330(2014).
RN   [53]
RP   INTERACTION WITH FGFR4.
RX   PubMed=26675719; DOI=10.1038/nature16449;
RA   Ulaganathan V.K., Sperl B., Rapp U.R., Ullrich A.;
RT   "Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding
RT   site.";
RL   Nature 528:570-574(2015).
RN   [54]
RP   INTERACTION WITH HHV-5 IMMEDIATE EARLY PROTEIN IE1 (MICROBIAL INFECTION).
RX   PubMed=27387064; DOI=10.1371/journal.ppat.1005748;
RA   Harwardt T., Lukas S., Zenger M., Reitberger T., Danzer D., Uebner T.,
RA   Munday D.C., Nevels M., Paulus C.;
RT   "Human Cytomegalovirus Immediate-Early 1 Protein Rewires Upstream STAT3 to
RT   Downstream STAT1 Signaling Switching an IL6-Type to an IFNgamma-Like
RT   Response.";
RL   PLoS Pathog. 12:e1005748-e1005748(2016).
RN   [55]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, ALLYSINE AT LYS-601; LYS-615;
RP   LYS-631 AND LYS-685, AND ACETYLATION AT LYS-601; LYS-615; LYS-631; LYS-685
RP   AND LYS-707.
RX   PubMed=28065600; DOI=10.1016/j.molcel.2016.12.002;
RA   Ma L., Huang C., Wang X.J., Xin D.E., Wang L.S., Zou Q.C., Zhang Y.S.,
RA   Tan M.D., Wang Y.M., Zhao T.C., Chatterjee D., Altura R.A., Wang C.,
RA   Xu Y.S., Yang J.H., Fan Y.S., Han B.H., Si J., Zhang X., Cheng J.,
RA   Chang Z., Chin Y.E.;
RT   "Lysyl oxidase 3 is a dual-specificity enzyme involved in STAT3
RT   deacetylation and deacetylimination modulation.";
RL   Mol. Cell 65:296-309(2017).
RN   [56]
RP   PHOSPHORYLATION AT TYR-640, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP   VARIANT ADMIO1 PHE-640.
RX   PubMed=29162862; DOI=10.1038/s41598-017-15912-6;
RA   Mori R., Wauman J., Icardi L., Van der Heyden J., De Cauwer L., Peelman F.,
RA   De Bosscher K., Tavernier J.;
RT   "TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional
RT   activity.";
RL   Sci. Rep. 7:15919-15919(2017).
RN   [57]
RP   INTERACTION WITH S.TYPHIMURIUM SARA (MICROBIAL INFECTION), AND
RP   PHOSPHORYLATION AT TYR-705 (MICROBIAL INFECTION).
RX   PubMed=29924996; DOI=10.1016/j.celrep.2018.05.072;
RA   Jaslow S.L., Gibbs K.D., Fricke W.F., Wang L., Pittman K.J., Mammel M.K.,
RA   Thaden J.T., Fowler V.G. Jr., Hammer G.E., Elfenbein J.R., Ko D.C.;
RT   "Salmonella Activation of STAT3 Signaling by SarA Effector Promotes
RT   Intracellular Replication and Production of IL-10.";
RL   Cell Rep. 23:3525-3536(2018).
RN   [58]
RP   RETRACTED PAPER.
RX   PubMed=31462771; DOI=10.1038/s41586-019-1511-x;
RA   Niu J., Sun Y., Chen B., Zheng B., Jarugumilli G.K., Walker S.R.,
RA   Hata A.N., Mino-Kenudson M., Frank D.A., Wu X.;
RT   "Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through
RT   S-palmitoylation.";
RL   Nature 573:139-143(2019).
RN   [59]
RP   RETRACTION NOTICE OF PUBMED:31462771.
RX   PubMed=32555452; DOI=10.1038/s41586-020-2414-6;
RA   Niu J., Sun Y., Chen B., Zheng B., Jarugumilli G.K., Walker S.R.,
RA   Hata A.N., Mino-Kenudson M., Frank D.A., Wu X.;
RL   Nature 583:154-154(2020).
RN   [60]
RP   FUNCTION, INTERACTION WITH CD274, AND PHOSPHORYLATION AT TYR-705.
RX   PubMed=32929201; DOI=10.1038/s41556-020-0575-z;
RA   Hou J., Zhao R., Xia W., Chang C.W., You Y., Hsu J.M., Nie L., Chen Y.,
RA   Wang Y.C., Liu C., Wang W.J., Wu Y., Ke B., Hsu J.L., Huang K., Ye Z.,
RA   Yang Y., Xia X., Li Y., Li C.W., Shao B., Tainer J.A., Hung M.C.;
RT   "PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in
RT   cancer cells and facilitates tumour necrosis.";
RL   Nat. Cell Biol. 22:1264-1275(2020).
RN   [61]
RP   SUBCELLULAR LOCATION, INTERACTION WITH PHB, PHOSPHORYLATION AT TYR-705 AND
RP   SER-727, AND TISSUE SPECIFICITY.
RX   PubMed=31899195; DOI=10.1016/j.imlet.2019.12.008;
RA   Zhang J., Sun Z., Wu Q., Shen J.;
RT   "Prohibitin 1 interacts with signal transducer and activator of
RT   transcription 3 in T-helper 17 cells.";
RL   Immunol. Lett. 219:8-14(2020).
RN   [62]
RP   IDENTIFICATION IN A COMPLEX WITH SLC39A6 AND SLC39A10.
RX   PubMed=32797246; DOI=10.1007/s00018-020-03616-6;
RA   Nimmanon T., Ziliotto S., Ogle O., Burt A., Gee J.M.W., Andrews G.K.,
RA   Kille P., Hogstrand C., Maret W., Taylor K.M.;
RT   "The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of
RT   mitosis.";
RL   Cell. Mol. Life Sci. 78:1781-1798(2021).
RN   [63]
RP   INTERACTION WITH OCIAD2.
RX   PubMed=29743632; DOI=10.1038/s41598-018-25667-3;
RA   Sinha S., Bheemsetty V.A., Inamdar M.S.;
RT   "A double helical motif in OCIAD2 is essential for its localization,
RT   interactions and STAT3 activation.";
RL   Sci. Rep. 8:7362-7362(2018).
RN   [64] {ECO:0007744|PDB:5U5S}
RP   STRUCTURE BY NMR OF 81-92 IN COMPLEX WITH BRD2, FUNCTION, ACETYLATION AT
RP   LYS-87, AND INTERACTION WITH BRD2.
RX   PubMed=28262505; DOI=10.1016/j.molcel.2016.12.022;
RA   Cheung K.L., Zhang F., Jaganathan A., Sharma R., Zhang Q., Konuma T.,
RA   Shen T., Lee J.Y., Ren C., Chen C.H., Lu G., Olson M.R., Zhang W.,
RA   Kaplan M.H., Littman D.R., Walsh M.J., Xiong H., Zeng L., Zhou M.M.;
RT   "Distinct roles of Brd2 and Brd4 in potentiating the transcriptional
RT   program for th17 cell differentiation.";
RL   Mol. Cell 65:1068-1080(2017).
RN   [65]
RP   VARIANTS HIES1 GLN-382; LEU-382; TRP-382; LEU-384; SER-384; GLN-423;
RP   VAL-463 DEL; ASN-611; VAL-621; ILE-622; LEU-637; MET-637; GLN-644 DEL AND
RP   CYS-657.
RX   PubMed=17881745; DOI=10.1056/nejmoa073687;
RA   Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N.,
RA   Freeman A.F., Demidowich A., Davis J., Turner M.L., Anderson V.L.,
RA   Darnell D.N., Welch P.A., Kuhns D.B., Frucht D.M., Malech H.L.,
RA   Gallin J.I., Kobayashi S.D., Whitney A.R., Voyich J.M., Musser J.M.,
RA   Woellner C., Schaffer A.A., Puck J.M., Grimbacher B.;
RT   "STAT3 mutations in the hyper-IgE syndrome.";
RL   N. Engl. J. Med. 357:1608-1619(2007).
RN   [66]
RP   VARIANTS HIES1 GLN-382; TRP-382; ILE-389; TYR-437 AND VAL-463 DEL, AND
RP   CHARACTERIZATION OF VARIANTS HIES1 GLN-382; TRP-382; ILE-389; TYR-437 AND
RP   VAL-463 DEL.
RX   PubMed=17676033; DOI=10.1038/nature06096;
RA   Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T.,
RA   Kawamura N., Ariga T., Pasic S., Stojkovic O., Metin A., Karasuyama H.;
RT   "Dominant-negative mutations in the DNA-binding domain of STAT3 cause
RT   hyper-IgE syndrome.";
RL   Nature 448:1058-1062(2007).
RN   [67]
RP   VARIANT HIES1 ILE-389.
RX   PubMed=23342295; DOI=10.2500/ar.2012.3.0035;
RA   Crosby K., Swender D., Chernin L., Hafez-Khayyata S., Ochs H.,
RA   Tcheurekdjian H., Hostoffer R.;
RT   "Signal transducer and activator of transcription 3 mutation with invasive
RT   eosinophilic disease.";
RL   Allergy Rhinol. (Providence) 3:E94-E97(2012).
RN   [68]
RP   VARIANTS ADMIO1 ARG-392; LYS-646; ASN-658 AND MET-716, AND INVOLVEMENT IN
RP   ADMIO1.
RX   PubMed=25038750; DOI=10.1038/ng.3040;
RA   Flanagan S.E., Haapaniemi E., Russell M.A., Caswell R., Lango Allen H.,
RA   De Franco E., McDonald T.J., Rajala H., Ramelius A., Barton J.,
RA   Heiskanen K., Heiskanen-Kosma T., Kajosaari M., Murphy N.P., Milenkovic T.,
RA   Seppaenen M., Lernmark A., Mustjoki S., Otonkoski T., Kere J., Morgan N.G.,
RA   Ellard S., Hattersley A.T.;
RT   "Activating germline mutations in STAT3 cause early-onset multi-organ
RT   autoimmune disease.";
RL   Nat. Genet. 46:812-814(2014).
RN   [69]
RP   VARIANTS ADMIO1 TRP-152; HIS-344; PHE-353; LYS-415; LYS-420; ARG-421;
RP   ILE-663; THR-703 AND MET-716, CHARACTERIZATION OF VARIANTS ADMIO1 TRP-152;
RP   HIS-344; PHE-353; LYS-415; LYS-420; ARG-421; THR-703 AND MET-716, AND
RP   INVOLVEMENT IN ADMIO1.
RX   PubMed=25359994; DOI=10.1182/blood-2014-09-602763;
RA   Milner J.D., Vogel T.P., Forbes L., Ma C.A., Stray-Pedersen A.,
RA   Niemela J.E., Lyons J.J., Engelhardt K.R., Zhang Y., Topcagic N.,
RA   Roberson E.D., Matthews H., Verbsky J.W., Dasu T., Vargas-Hernandez A.,
RA   Varghese N., McClain K.L., Karam L.B., Nahmod K., Makedonas G., Mace E.M.,
RA   Sorte H.S., Perminow G., Rao V.K., O'Connell M.P., Price S., Su H.C.,
RA   Butrick M., McElwee J., Hughes J.D., Willet J., Swan D., Xu Y.,
RA   Santibanez-Koref M., Slowik V., Dinwiddie D.L., Ciaccio C.E.,
RA   Saunders C.J., Septer S., Kingsmore S.F., White A.J., Cant A.J.,
RA   Hambleton S., Cooper M.A.;
RT   "Early-onset lymphoproliferation and autoimmunity caused by germline STAT3
RT   gain-of-function mutations.";
RL   Blood 125:591-599(2015).
RN   [70]
RP   VARIANTS HIES1 TRP-382; TYR-395; TYR-425; MET-637 AND CYS-657,
RP   CHARACTERIZATION OF VARIANTS HIES1 TRP-382; TYR-395; TYR-425; MET-637 AND
RP   CYS-657, AND PHOSPHORYLATION AT TYR-705 AND SER-727.
RX   PubMed=26293184; DOI=10.1111/cge.12658;
RA   Alcantara-Montiel J.C., Staines-Boone T., Lopez-Herrera G.,
RA   Espinosa-Rosales F., Espinosa-Padilla S.E., Hernandez-Rivas R.,
RA   Santos-Argumedo L.;
RT   "Functional characterization of two new STAT3 mutations associated with
RT   hyper-IgE syndrome in a Mexican cohort.";
RL   Clin. Genet. 89:217-221(2016).
RN   [71]
RP   VARIANTS ADMIO1 HIS-278 AND THR-394, AND CHARACTERIZATION OF VARIANTS
RP   ADMIO1 HIS-278; ARG-392 AND THR-394.
RX   PubMed=28579554; DOI=10.1016/j.clim.2017.05.021;
RA   Nabhani S., Schipp C., Miskin H., Levin C., Postovsky S., Dujovny T.,
RA   Koren A., Harlev D., Bis A.M., Auer F., Keller B., Warnatz K., Gombert M.,
RA   Ginzel S., Borkhardt A., Stepensky P., Fischer U.;
RT   "STAT3 gain-of-function mutations associated with autoimmune
RT   lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis
RT   and can be targeted by BH3 mimetic compounds.";
RL   Clin. Immunol. 181:32-42(2017).
RN   [72]
RP   VARIANT ADMIO1 LEU-715, AND INVOLVEMENT IN ADMIO1.
RX   PubMed=28253502; DOI=10.1159/000456544;
RA   Sediva H., Dusatkova P., Kanderova V., Obermannova B., Kayserova J.,
RA   Sramkova L., Zemkova D., Elblova L., Svaton M., Zachova R., Kolouskova S.,
RA   Fronkova E., Sumnik Z., Sediva A., Lebl J., Pruhova S.;
RT   "Short stature in a boy with multiple early-onset autoimmune conditions due
RT   to a STAT3 activating mutation: could intracellular growth hormone
RT   signalling be compromised?";
RL   Horm. Res. Paediatr. 88:160-166(2017).
RN   [73]
RP   VARIANT ADMIO1 SER-330, AND CHARACTERIZATION OF VARIANT ADMIO1 SER-330.
RX   PubMed=28073828; DOI=10.2337/db16-0867;
RA   Velayos T., Martinez R., Alonso M., Garcia-Etxebarria K., Aguayo A.,
RA   Camarero C., Urrutia I., Martinez de LaPiscina I., Barrio R., Santin I.,
RA   Castano L.;
RT   "An activating mutation in STAT3 results in neonatal diabetes through
RT   reduced insulin synthesis.";
RL   Diabetes 66:1022-1029(2017).
RN   [74]
RP   VARIANTS ADMIO1 HIS-70; TRP-103; TRP-107; TRP-152; ARG-162; ASP-166;
RP   LYS-166; SER-174; ALA-218; PRO-260; CYS-278; HIS-278; GLN-302; TRP-325;
RP   ARG-331; HIS-344; PHE-353; ARG-361; ARG-387; ALA-389; ARG-389; SER-389;
RP   THR-394; LEU-408; GLN-415; LYS-415; GLY-415; ARG-419; LYS-420; ARG-421;
RP   ARG-422; ILE-443; ASP-447; GLU-448; LYS-506; ARG-546; PHE-640; ARG-643;
RP   LYS-646; ARG-658; ILE-663; TYR-664; LEU-715 AND MET-716.
RX   PubMed=36228738; DOI=10.1016/j.jaci.2022.09.002;
RG   STAT3 GOF Working Group;
RA   Leiding J.W., Vogel T.P., Santarlas V.G.J., Mhaskar R., Smith M.R.,
RA   Carisey A., Vargas-Hernandez A., Silva-Carmona M., Heeg M., Rensing-Ehl A.,
RA   Neven B., Hadjadj J., Hambleton S., Ronan Leahy T., Meesilpavikai K.,
RA   Cunningham-Rundles C., Dutmer C.M., Sharapova S.O., Taskinen M., Chua I.,
RA   Hague R., Klemann C., Kostyuchenko L., Morio T., Thatayatikom A., Ozen A.,
RA   Scherbina A., Bauer C.S., Flanagan S.E., Gambineri E., Giovannini-Chami L.,
RA   Heimall J., Sullivan K.E., Allenspach E., Romberg N., Deane S.G.,
RA   Prince B.T., Rose M.J., Bohnsack J., Mousallem T., Jesudas R.,
RA   Santos Vilela M.M.D., O'Sullivan M., Pachlopnik Schmid J., Pruhova S.,
RA   Klocperk A., Rees M., Su H., Bahna S., Baris S., Bartnikas L.M.,
RA   Chang Berger A., Briggs T.A., Brothers S., Bundy V., Chan A.Y.,
RA   Chandrakasan S., Christiansen M., Cole T., Cook M.C., Desai M.M.,
RA   Fischer U., Fulcher D.A., Gallo S., Gauthier A., Gennery A.R.,
RA   Goncalo Marques J., Gottrand F., Grimbacher B., Grunebaum E.,
RA   Haapaniemi E., Haemaelaeinen S., Heiskanen K., Heiskanen-Kosma T.,
RA   Hoffman H.M., Gonzalez-Granado L.I., Guerrerio A.L., Kainulainen L.,
RA   Kumar A., Lawrence M.G., Levin C., Martelius T., Neth O., Olbrich P.,
RA   Palma A., Patel N.C., Pozos T., Preece K., Lugo Reyes S.O., Russell M.A.,
RA   Schejter Y., Seroogy C., Sinclair J., Skevofilax E., Suan D., Suez D.,
RA   Szabolcs P., Velasco H., Warnatz K., Walkovich K., Worth A.,
RA   Seppaenen M.R.J., Torgerson T.R., Sogkas G., Ehl S., Tangye S.G.,
RA   Cooper M.A., Milner J.D., Forbes Satter L.R.;
RT   "Monogenic early-onset lymphoproliferation and autoimmunity: Natural
RT   history of STAT3 gain-of-function syndrome.";
RL   J. Allergy Clin. Immunol. 151:1081-1095(2023).
RN   [75]
RP   ERRATUM OF PUBMED:36228738.
RX   PubMed=38582550; DOI=10.1016/j.jaci.2024.02.001;
RA   Leiding J.W., Vogel T.P., Santarlas V.G.J., Mhaskar R., Smith M.R.,
RA   Carisey A., Vargas-Hernandez A., Silva-Carmona M., Heeg M., Rensing-Ehl A.,
RA   Neven B., Hadjadj J., Hambleton S., Ronan Leahy T., Meesilpavikai K.,
RA   Cunningham-Rundles C., Dutmer C.M., Sharapova S.O., Taskinen M., Chua I.,
RA   Hague R., Klemann C., Kostyuchenko L., Morio T., Thatayatikom A., Ozen A.,
RA   Scherbina A., Bauer C.S., Flanagan S.E., Gambineri E., Giovannini-Chami L.,
RA   Heimall J., Sullivan K.E., Allenspach E., Romberg N., Deane S.G.,
RA   Prince B.T., Rose M.J., Bohnsack J., Mousallem T., Jesudas R.,
RA   Santos Vilela M.M.D., O'Sullivan M., Pachlopnik Schmid J., Pruhova S.,
RA   Klocperk A., Rees M., Su H., Bahna S., Baris S., Bartnikas L.M.,
RA   Chang Berger A., Briggs T.A., Brothers S., Bundy V., Chan A.Y.,
RA   Chandrakasan S., Christiansen M., Cole T., Cook M.C., Desai M.M.,
RA   Fischer U., Fulcher D.A., Gallo S., Gauthier A., Gennery A.R.,
RA   Goncalo Marques J., Gottrand F., Grimbacher B., Grunebaum E.,
RA   Haapaniemi E., Haemaelaeinen S., Heiskanen K., Heiskanen-Kosma T.,
RA   Hoffman H.M., Gonzalez-Granado L.I., Guerrerio A.L., Kainulainen L.,
RA   Kumar A., Lawrence M.G., Levin C., Martelius T., Neth O., Olbrich P.,
RA   Palma A., Patel N.C., Pozos T., Preece K., Lugo Reyes S.O., Russell M.A.,
RA   Schejter Y., Seroogy C., Sinclair J., Skevofilax E., Suan D., Suez D.,
RA   Szabolcs P., Velasco H., Warnatz K., Walkovich K., Worth A.,
RA   Seppaenen M.R.J., Torgerson T.R., Sogkas G., Ehl S., Tangye S.G.,
RA   Cooper M.A., Milner J.D., Forbes Satter L.R.;
RL   J. Allergy Clin. Immunol. 153:1167-1167(2024).
RN   [76]
RP   VARIANT ADMIO1 LYS-357, CHARACTERIZATION OF VARIANT ADMIO1 LYS-357, AND
RP   FUNCTION.
RX   PubMed=38404237; DOI=10.1002/mgg3.2407;
RA   Zhou Q., Chen D., Yu J., Zheng B., Zhou W., Jia Z., Zhang A., Gu W.;
RT   "A novel gain-of-function STAT3 variant in infantile-onset diabetes
RT   associated with multiorgan autoimmunity.";
RL   Mol. Genet. Genomic Med. 12:e2407-e2407(2024).
CC   -!- FUNCTION: Signal transducer and transcription activator that mediates
CC       cellular responses to interleukins, KITLG/SCF, LEP and other growth
CC       factors (PubMed:10688651, PubMed:12359225, PubMed:12873986,
CC       PubMed:15194700, PubMed:15653507, PubMed:16285960, PubMed:17344214,
CC       PubMed:18242580, PubMed:18782771, PubMed:22306293, PubMed:23084476,
CC       PubMed:28262505, PubMed:32929201, PubMed:38404237). Once activated,
CC       recruits coactivators, such as NCOA1 or MED1, to the promoter region of
CC       the target gene (PubMed:15653507, PubMed:16285960, PubMed:17344214,
CC       PubMed:18782771, PubMed:28262505, PubMed:32929201). May mediate
CC       cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4
CC       (PubMed:12873986). Upon activation of IL6ST/gp130 signaling by
CC       interleukin-6 (IL6), binds to the IL6-responsive elements identified in
CC       the promoters of various acute-phase protein genes (PubMed:12359225).
CC       Activated by IL31 through IL31RA (PubMed:15194700). Acts as a regulator
CC       of inflammatory response by regulating differentiation of naive CD4(+)
CC       T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation
CC       promotes its transcription activity and cell differentiation while
CC       deacetylation and oxidation of lysine residues by LOXL3 inhibits
CC       differentiation (PubMed:28065600, PubMed:28262505). Involved in cell
CC       cycle regulation by inducing the expression of key genes for the
CC       progression from G1 to S phase, such as CCND1 (PubMed:17344214).
CC       Mediates the effects of LEP on melanocortin production, body energy
CC       homeostasis and lactation (By similarity). May play an apoptotic role
CC       by transctivating BIRC5 expression under LEP activation
CC       (PubMed:18242580). Cytoplasmic STAT3 represses macroautophagy by
CC       inhibiting EIF2AK2/PKR activity (PubMed:23084476). Plays a crucial role
CC       in basal beta cell functions, such as regulation of insulin secretion
CC       (By similarity). Following JAK/STAT signaling activation and as part of
CC       a complex with NFATC3 and NFATC4, binds to the alpha-beta E4 promoter
CC       region of CRYAB and activates transcription in cardiomyocytes (By
CC       similarity). {ECO:0000250|UniProtKB:P42227,
CC       ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:12359225,
CC       ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15194700,
CC       ECO:0000269|PubMed:15653507, ECO:0000269|PubMed:16285960,
CC       ECO:0000269|PubMed:17344214, ECO:0000269|PubMed:18242580,
CC       ECO:0000269|PubMed:18782771, ECO:0000269|PubMed:22306293,
CC       ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:28065600,
CC       ECO:0000269|PubMed:28262505, ECO:0000269|PubMed:32929201,
CC       ECO:0000269|PubMed:38404237}.
CC   -!- SUBUNIT: Forms a homodimer or a heterodimer with a related family
CC       member (at least STAT1) (PubMed:15653507, PubMed:28065600). Component
CC       of a promoter-binding complex composed of STAT3, NFATC3 and NFATC4;
CC       complex formation is enhanced by calcineurin (By similarity). Interacts
CC       with IL31RA, NCOA1, PELP1, SIPAR, SOCS7, STATIP1 and TMF1 (By
CC       similarity) (PubMed:15194700, PubMed:15467733, PubMed:15677474,
CC       PubMed:15994929, PubMed:17344214). Interacts with IL23R in presence of
CC       IL23 (PubMed:12023369). Interacts (via SH2 domain) with NLK. Interacts
CC       with ARL2BP; the interaction is enhanced by LIF and JAK1 expression (By
CC       similarity). Interacts with KPNA4 and KPNA5; KPNA4 may be the primary
CC       mediator of nuclear import (By similarity). Interacts with CAV2; the
CC       interaction is increased on insulin-induced tyrosine phosphorylation of
CC       CAV2 and leads to STAT3 activation (By similarity). Interacts with
CC       ARL2BP; interaction is enhanced with ARL2 (PubMed:18234692). Interacts
CC       with NEK6 (By similarity). Binds to CDK9 when activated and nuclear
CC       (PubMed:17956865). Interacts with BMX (PubMed:10688651). Interacts with
CC       ZIPK/DAPK3 (PubMed:16219639). Interacts with PIAS3; the interaction
CC       occurs on stimulation by IL6, CNTF or OSM and inhibits the DNA binding
CC       activity of STAT3 (PubMed:9388184). In prostate cancer cells, interacts
CC       with PRKCE and promotes DNA binding activity of STAT3
CC       (PubMed:17875724). Interacts with STMN3, antagonizing its microtubule-
CC       destabilizing activity (By similarity). Interacts with the 'Lys-129'
CC       acetylated form of BIRC5/survivin (PubMed:20826784). Interacts with FER
CC       (PubMed:19147545). Interacts (via SH2 domain) with EIF2AK2/PKR (via the
CC       kinase catalytic domain) (PubMed:23084476). Interacts with INPP5F; the
CC       interaction is independent of STAT3 Tyr-705 phosphorylation status
CC       (PubMed:25476455). Interacts with FGFR4 (PubMed:26675719). Interacts
CC       with OCIAD1 (By similarity). Interacts with OCIAD2 (PubMed:29743632).
CC       Interacts (unphosphorylated or phosphorylated at Ser-727) with PHB1
CC       (PubMed:31899195). Interacts and may form heterodimers with NHLH1 (By
CC       similarity). Found in a complex with SLC39A6, SLC39A10 and with the
CC       'Ser-727' phosphorylated form of STAT3 throughout mitosis
CC       (PubMed:32797246). Interacts (when phosphorylated at Tyr-705) with
CC       CD274/PD-L1; promoting nuclear translocation of CD274/PD-L1
CC       (PubMed:32929201). Interacts (when acetylated) with EP300 (via bromo
CC       domain); interaction takes place following STAT3 acetylation by EP300
CC       and promotes enhanceosome assembly (PubMed:18782771). Interacts (when
CC       acetylated) with BRD2 (via bromo domain); interaction promotes STAT3
CC       recruitment to chromatin and T-helper Th17 cell differentiation
CC       (PubMed:28262505). Interacts with FAM220A/SIPAR; the interaction occurs
CC       in both the nucleus and the cytoplasm, is enhanced by IL6 and promotes
CC       STAT3 dephosphorylation (By similarity). Interacts in both
CC       unphosphorylated and phosphorylated forms with FAM220A but interacts
CC       preferentially in the phosphorylated form in the nucleus (By
CC       similarity). Interacts with PTPN2; the interaction is promoted by
CC       FAM220A and leads to STAT3 dephosphorylation which negatively regulates
CC       STAT3 transcriptional activator activity (By similarity).
CC       {ECO:0000250|UniProtKB:P42227, ECO:0000250|UniProtKB:P52631,
CC       ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:11773079,
CC       ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:12873986,
CC       ECO:0000269|PubMed:15194700, ECO:0000269|PubMed:15467733,
CC       ECO:0000269|PubMed:15653507, ECO:0000269|PubMed:15677474,
CC       ECO:0000269|PubMed:15994929, ECO:0000269|PubMed:16219639,
CC       ECO:0000269|PubMed:17344214, ECO:0000269|PubMed:17875724,
CC       ECO:0000269|PubMed:17956865, ECO:0000269|PubMed:18070987,
CC       ECO:0000269|PubMed:18234692, ECO:0000269|PubMed:18782771,
CC       ECO:0000269|PubMed:19147545, ECO:0000269|PubMed:20826784,
CC       ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25476455,
CC       ECO:0000269|PubMed:26675719, ECO:0000269|PubMed:28065600,
CC       ECO:0000269|PubMed:28262505, ECO:0000269|PubMed:29743632,
CC       ECO:0000269|PubMed:31899195, ECO:0000269|PubMed:32797246,
CC       ECO:0000269|PubMed:32929201, ECO:0000269|PubMed:9388184}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV core protein.
CC       {ECO:0000269|PubMed:12208879}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with S.typhimurium SarA.
CC       {ECO:0000269|PubMed:29924996}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus
CC       (HHV-5) immediate early protein IE1; this interaction leads to STAT3
CC       nuclear accumulation and disruption of IL6-induced STAT3
CC       phosphorylation. {ECO:0000269|PubMed:27387064}.
CC   -!- INTERACTION:
CC       P40763; O14874: BCKDK; NbExp=2; IntAct=EBI-518675, EBI-1046765;
CC       P40763; Q96G01: BICD1; NbExp=2; IntAct=EBI-518675, EBI-1104509;
CC       P40763; P51451: BLK; NbExp=9; IntAct=EBI-518675, EBI-2105445;
CC       P40763; P51813: BMX; NbExp=8; IntAct=EBI-518675, EBI-696657;
CC       P40763; P07384: CAPN1; NbExp=2; IntAct=EBI-518675, EBI-1542113;
CC       P40763; P50750: CDK9; NbExp=2; IntAct=EBI-518675, EBI-1383449;
CC       P40763; P31146: CORO1A; NbExp=2; IntAct=EBI-518675, EBI-1046676;
CC       P40763; Q99062: CSF3R; NbExp=4; IntAct=EBI-518675, EBI-7331284;
CC       P40763; Q9UER7: DAXX; NbExp=4; IntAct=EBI-518675, EBI-77321;
CC       P40763; O95661: DIRAS3; NbExp=3; IntAct=EBI-518675, EBI-6139214;
CC       P40763; Q13011: ECH1; NbExp=2; IntAct=EBI-518675, EBI-711968;
CC       P40763; P30084: ECHS1; NbExp=3; IntAct=EBI-518675, EBI-719602;
CC       P40763; P00533: EGFR; NbExp=15; IntAct=EBI-518675, EBI-297353;
CC       P40763; P04626: ERBB2; NbExp=9; IntAct=EBI-518675, EBI-641062;
CC       P40763; Q15910: EZH2; NbExp=5; IntAct=EBI-518675, EBI-530054;
CC       P40763; Q8TAE8: GADD45GIP1; NbExp=4; IntAct=EBI-518675, EBI-372506;
CC       P40763; Q9BVP2: GNL3; NbExp=2; IntAct=EBI-518675, EBI-641642;
CC       P40763; P12268: IMPDH2; NbExp=3; IntAct=EBI-518675, EBI-353389;
CC       P40763; P23458: JAK1; NbExp=2; IntAct=EBI-518675, EBI-1383438;
CC       P40763; Q07666: KHDRBS1; NbExp=2; IntAct=EBI-518675, EBI-1364;
CC       P40763; P25791: LMO2; NbExp=3; IntAct=EBI-518675, EBI-739696;
CC       P40763; O43318: MAP3K7; NbExp=4; IntAct=EBI-518675, EBI-358684;
CC       P40763; O15264: MAPK13; NbExp=2; IntAct=EBI-518675, EBI-2116951;
CC       P40763; P45984: MAPK9; NbExp=2; IntAct=EBI-518675, EBI-713568;
CC       P40763; P45984-1: MAPK9; NbExp=3; IntAct=EBI-518675, EBI-713586;
CC       P40763; Q8TE76: MORC4; NbExp=2; IntAct=EBI-518675, EBI-3940432;
CC       P40763; Q92665: MRPS31; NbExp=2; IntAct=EBI-518675, EBI-720602;
CC       P40763; Q16236: NFE2L2; NbExp=5; IntAct=EBI-518675, EBI-2007911;
CC       P40763; Q14938-3: NFIX; NbExp=3; IntAct=EBI-518675, EBI-20559045;
CC       P40763; Q14938-4: NFIX; NbExp=3; IntAct=EBI-518675, EBI-20558886;
CC       P40763; P22736: NR4A1; NbExp=3; IntAct=EBI-518675, EBI-721550;
CC       P40763; Q9ULD0: OGDHL; NbExp=2; IntAct=EBI-518675, EBI-3940481;
CC       P40763; P06401: PGR; NbExp=3; IntAct=EBI-518675, EBI-78539;
CC       P40763; Q96HA1-2: POM121; NbExp=3; IntAct=EBI-518675, EBI-11956563;
CC       P40763; P32119: PRDX2; NbExp=4; IntAct=EBI-518675, EBI-1266300;
CC       P40763; Q14289: PTK2B; NbExp=4; IntAct=EBI-518675, EBI-298640;
CC       P40763; P18031: PTPN1; NbExp=2; IntAct=EBI-518675, EBI-968788;
CC       P40763; Q04206: RELA; NbExp=4; IntAct=EBI-518675, EBI-73886;
CC       P40763; P07949: RET; NbExp=3; IntAct=EBI-518675, EBI-2480756;
CC       P40763; O75116: ROCK2; NbExp=3; IntAct=EBI-518675, EBI-366288;
CC       P40763; P46781: RPS9; NbExp=2; IntAct=EBI-518675, EBI-351206;
CC       P40763; O00570: SOX1; NbExp=2; IntAct=EBI-518675, EBI-2935583;
CC       P40763; P08047: SP1; NbExp=4; IntAct=EBI-518675, EBI-298336;
CC       P40763; P30626: SRI; NbExp=3; IntAct=EBI-518675, EBI-750459;
CC       P40763; P42224: STAT1; NbExp=10; IntAct=EBI-518675, EBI-1057697;
CC       P40763; P40763: STAT3; NbExp=8; IntAct=EBI-518675, EBI-518675;
CC       P40763; Q06520: SULT2A1; NbExp=2; IntAct=EBI-518675, EBI-3921363;
CC       P40763; P43405: SYK; NbExp=10; IntAct=EBI-518675, EBI-78302;
CC       P40763; Q810M5: Zdhhc19; Xeno; NbExp=4; IntAct=EBI-518675, EBI-22225085;
CC       P40763; Q9DUM3; Xeno; NbExp=4; IntAct=EBI-518675, EBI-7971837;
CC       P40763-2; P05067: APP; NbExp=3; IntAct=EBI-10692009, EBI-77613;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15653507,
CC       ECO:0000269|PubMed:16285960, ECO:0000269|PubMed:28065600,
CC       ECO:0000269|PubMed:31899195}. Nucleus {ECO:0000269|PubMed:15653507,
CC       ECO:0000269|PubMed:16285960, ECO:0000269|PubMed:28065600,
CC       ECO:0000269|PubMed:29162862, ECO:0000269|PubMed:31899195}.
CC       Note=Shuttles between the nucleus and the cytoplasm (PubMed:29162862).
CC       Translocated into the nucleus upon tyrosine phosphorylation and
CC       dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3
CC       or FGFR4 (PubMed:15653507, PubMed:16285960). Constitutive nuclear
CC       presence is independent of tyrosine phosphorylation. Predominantly
CC       present in the cytoplasm without stimuli. Upon leukemia inhibitory
CC       factor (LIF) stimulation, accumulates in the nucleus. The complex
CC       composed of BART and ARL2 plays an important role in the nuclear
CC       translocation and retention of STAT3. Identified in a complex with LYN
CC       and PAG1. Translocates to the nucleus in the presence of EDN1 (By
CC       similarity). {ECO:0000250|UniProtKB:P52631,
CC       ECO:0000269|PubMed:15653507, ECO:0000269|PubMed:16285960,
CC       ECO:0000269|PubMed:29162862}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P40763-1; Sequence=Displayed;
CC       Name=Del-701;
CC         IsoId=P40763-2; Sequence=VSP_010474;
CC       Name=3;
CC         IsoId=P40763-3; Sequence=VSP_055918, VSP_055919;
CC   -!- TISSUE SPECIFICITY: Heart, brain, placenta, lung, liver, skeletal
CC       muscle, kidney and pancreas. Expressed in naive CD4(+) T cells as well
CC       as T-helper Th17, Th1 and Th2 cells (PubMed:31899195).
CC       {ECO:0000269|PubMed:31899195}.
CC   -!- PTM: Tyrosine phosphorylated upon stimulation with EGF. Tyrosine
CC       phosphorylated in response to constitutively activated FGFR1, FGFR2,
CC       FGFR3 and FGFR4 (By similarity). Activated through tyrosine
CC       phosphorylation by BMX. Tyrosine phosphorylated in response to IL6,
CC       IL11, LIF, CNTF, KITLG/SCF, CSF1, EGF, PDGF, IFN-alpha, LEP and OSM.
CC       Activated KIT promotes phosphorylation on tyrosine residues and
CC       subsequent translocation to the nucleus. Phosphorylated on serine upon
CC       DNA damage, probably by ATM or ATR. Serine phosphorylation is important
CC       for the formation of stable DNA-binding STAT3 homodimers and maximal
CC       transcriptional activity. ARL2BP may participate in keeping the
CC       phosphorylated state of STAT3 within the nucleus. Upon LPS challenge,
CC       phosphorylated within the nucleus by IRAK1. Upon erythropoietin
CC       treatment, phosphorylated on Ser-727 by RPS6KA5. Dephosphorylation on
CC       tyrosine residues by PTPN2 negatively regulates IL6/interleukin-6
CC       signaling (By similarity). Phosphorylation at Tyr-705 by PTK6, isoform
CC       M2 of PKM (PKM2) or FER leads to an increase of its transcriptional
CC       activity (PubMed:12763138, PubMed:16568091, PubMed:21135090,
CC       PubMed:22306293, PubMed:32929201). Phosphorylation at Tyr-705 is
CC       increased in the presence of calcineurin (By similarity).
CC       Phosphorylation at Tyr-640 by TYK2 negatively regulates transcriptional
CC       activity (PubMed:29162862). {ECO:0000250|UniProtKB:P42227,
CC       ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:12359225,
CC       ECO:0000269|PubMed:12763138, ECO:0000269|PubMed:15465816,
CC       ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:16568091,
CC       ECO:0000269|PubMed:17344214, ECO:0000269|PubMed:17875724,
CC       ECO:0000269|PubMed:18234692, ECO:0000269|PubMed:18599021,
CC       ECO:0000269|PubMed:19147545, ECO:0000269|PubMed:21135090,
CC       ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:29162862,
CC       ECO:0000269|PubMed:32929201, ECO:0000269|PubMed:7701321}.
CC   -!- PTM: Acetylated on lysine residues by EP300/p300, promoting its
CC       activation (PubMed:15653507, PubMed:16285960, PubMed:18782771).
CC       Acetylation at Lys-49 and Lys-87 by EP300/p300 promotes its activation
CC       (PubMed:15653507, PubMed:16285960, PubMed:28262505). Acetylation at
CC       Lys-87 by EP300/p300 promotes its association with BRD2 and recruitment
CC       to chromatin (PubMed:28262505). Deacetylated at Lys-49 and Lys-87 by
CC       HDAC1 (PubMed:16285960). Acetylation at Lys-685 by EP300/p300 promotes
CC       its homodimerization and activation (PubMed:15653507). Deacetylated at
CC       Lys-685 by HDAC3 (PubMed:15653507). Acetylated on lysine residues by
CC       CREBBP (PubMed:28065600). Deacetylation by LOXL3 leads to disrupt STAT3
CC       dimerization and inhibit STAT3 transcription activity
CC       (PubMed:28065600). Oxidation of lysine residues to allysine on STAT3
CC       preferentially takes place on lysine residues that are acetylated
CC       (PubMed:28065600). {ECO:0000269|PubMed:15653507,
CC       ECO:0000269|PubMed:16285960, ECO:0000269|PubMed:18782771,
CC       ECO:0000269|PubMed:28065600, ECO:0000269|PubMed:28262505}.
CC   -!- PTM: Some lysine residues are oxidized to allysine by LOXL3, leading to
CC       disrupt STAT3 dimerization and inhibit STAT3 transcription activity
CC       (PubMed:28065600). Oxidation of lysine residues to allysine on STAT3
CC       preferentially takes place on lysine residues that are acetylated
CC       (PubMed:28065600). {ECO:0000269|PubMed:28065600}.
CC   -!- PTM: (Microbial infection) Phosphorylated on Tyr-705 in the presence of
CC       S.typhimurium SarA. {ECO:0000269|PubMed:29924996}.
CC   -!- DISEASE: Hyper-IgE syndrome 1, autosomal dominant, with recurrent
CC       infections (HIES1) [MIM:147060]: A rare disorder of immunity and
CC       connective tissue characterized by immunodeficiency, chronic
CC       eosinophilia, distinctive coarse facial appearance, abnormal dentition,
CC       hyperextensibility of the joints, and bone fractures.
CC       {ECO:0000269|PubMed:17676033, ECO:0000269|PubMed:17881745,
CC       ECO:0000269|PubMed:23342295, ECO:0000269|PubMed:26293184}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Autoimmune disease, multisystem, infantile-onset, 1 (ADMIO1)
CC       [MIM:615952]: A disorder characterized by early childhood onset of a
CC       spectrum of autoimmune manifestations affecting multiple organs,
CC       including insulin-dependent diabetes mellitus and autoimmune
CC       enteropathy or celiac disease. Other features include short stature,
CC       non-specific dermatitis, hypothyroidism, autoimmune arthritis, and
CC       delayed puberty. {ECO:0000269|PubMed:25038750,
CC       ECO:0000269|PubMed:25359994, ECO:0000269|PubMed:28073828,
CC       ECO:0000269|PubMed:28253502, ECO:0000269|PubMed:28579554,
CC       ECO:0000269|PubMed:29162862, ECO:0000269|PubMed:36228738,
CC       ECO:0000269|PubMed:38404237}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Involved in the gp130-mediated signaling pathway.
CC   -!- SIMILARITY: Belongs to the transcription factor STAT family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was shown to be S-palmitoylated by ZDHHC19, leading to STAT3
CC       homodimerization. However, this study was later retracted.
CC       {ECO:0000305|PubMed:31462771, ECO:0000305|PubMed:32555452}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=STAT3 entry;
CC       URL="https://en.wikipedia.org/wiki/STAT3";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/444/STAT3";
CC   -!- WEB RESOURCE: Name=STAT3base; Note=STAT3 mutation db;
CC       URL="https://databases.lovd.nl/shared/genes/STAT3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L29277; AAA58374.1; -; mRNA.
DR   EMBL; AJ012463; CAA10032.1; -; mRNA.
DR   EMBL; JB252046; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK291933; BAF84622.1; -; mRNA.
DR   EMBL; AY572796; AAS66986.1; -; Genomic_DNA.
DR   EMBL; AC087691; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471152; EAW60822.1; -; Genomic_DNA.
DR   EMBL; BC000627; AAH00627.1; -; mRNA.
DR   EMBL; BC014482; AAH14482.1; -; mRNA.
DR   EMBL; AF029311; AAB84254.1; -; mRNA.
DR   CCDS; CCDS32656.1; -. [P40763-1]
DR   CCDS; CCDS32657.1; -. [P40763-2]
DR   CCDS; CCDS59288.1; -. [P40763-3]
DR   PIR; A54444; A54444.
DR   RefSeq; NP_001356441.1; NM_001369512.1. [P40763-1]
DR   RefSeq; NP_001356442.1; NM_001369513.1. [P40763-1]
DR   RefSeq; NP_001356443.1; NM_001369514.1. [P40763-2]
DR   RefSeq; NP_001356445.1; NM_001369516.1. [P40763-2]
DR   RefSeq; NP_001356446.1; NM_001369517.1. [P40763-3]
DR   RefSeq; NP_001356447.1; NM_001369518.1. [P40763-3]
DR   RefSeq; NP_003141.2; NM_003150.3. [P40763-2]
DR   RefSeq; NP_644805.1; NM_139276.3. [P40763-1]
DR   RefSeq; NP_998827.1; NM_213662.2. [P40763-3]
DR   RefSeq; XP_005257673.2; XM_005257616.3.
DR   RefSeq; XP_005257674.2; XM_005257617.3.
DR   RefSeq; XP_011523447.1; XM_011525145.2.
DR   RefSeq; XP_011523448.1; XM_011525146.2.
DR   RefSeq; XP_016880461.1; XM_017024972.1.
DR   RefSeq; XP_016880464.1; XM_017024975.1.
DR   RefSeq; XP_047292541.1; XM_047436585.1. [P40763-3]
DR   RefSeq; XP_054172966.1; XM_054316991.1. [P40763-3]
DR   PDB; 5AX3; X-ray; 2.98 A; B=571-582.
DR   PDB; 5U5S; NMR; -; B=81-92.
DR   PDB; 6NJS; X-ray; 2.70 A; A=127-688.
DR   PDB; 6NUQ; X-ray; 3.15 A; A=127-688.
DR   PDB; 6QHD; X-ray; 2.85 A; A/B=127-715.
DR   PDB; 6TLC; X-ray; 2.90 A; A/B=127-722.
DR   PDBsum; 5AX3; -.
DR   PDBsum; 5U5S; -.
DR   PDBsum; 6NJS; -.
DR   PDBsum; 6NUQ; -.
DR   PDBsum; 6QHD; -.
DR   PDBsum; 6TLC; -.
DR   AlphaFoldDB; P40763; -.
DR   SMR; P40763; -.
DR   BioGRID; 112651; 438.
DR   ComplexPortal; CPX-6041; STAT1/STAT3 complex.
DR   ComplexPortal; CPX-6043; STAT3/STAT5A complex.
DR   ComplexPortal; CPX-6044; STAT3/STAT5B complex.
DR   ComplexPortal; CPX-6046; STAT3/STAT4 complex.
DR   ComplexPortal; CPX-6049; STAT3 homodimer.
DR   CORUM; P40763; -.
DR   DIP; DIP-33584N; -.
DR   ELM; P40763; -.
DR   FunCoup; P40763; 3234.
DR   IntAct; P40763; 305.
DR   MINT; P40763; -.
DR   STRING; 9606.ENSP00000264657; -.
DR   BindingDB; P40763; -.
DR   ChEMBL; CHEMBL4026; -.
DR   DrugBank; DB00459; Acitretin.
DR   DrugBank; DB05513; Atiprimod.
DR   DrugBank; DB00482; Celecoxib.
DR   DrugBank; DB11259; Diosmetin.
DR   DrugBank; DB05959; ENMD-1198.
DR   DrugBank; DB12116; Epigallocatechin gallate.
DR   DrugBank; DB05475; Golotimod.
DR   DrugBank; DB15584; Luteolin.
DR   DrugBank; DB16051; MOL-4239.
DR   DrugBank; DB12155; Napabucasin.
DR   DrugBank; DB17490; NT-219.
DR   DrugBank; DB16630; OPB-111077.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB17578; TTI-101.
DR   DrugBank; DB12679; WP-1066.
DR   DrugCentral; P40763; -.
DR   GuidetoPHARMACOLOGY; 2994; -.
DR   MoonDB; P40763; Predicted.
DR   GlyCosmos; P40763; 6 sites, 2 glycans.
DR   GlyGen; P40763; 7 sites, 2 O-linked glycans (6 sites).
DR   iPTMnet; P40763; -.
DR   MetOSite; P40763; -.
DR   PhosphoSitePlus; P40763; -.
DR   SwissPalm; P40763; -.
DR   BioMuta; STAT3; -.
DR   DMDM; 48429227; -.
DR   CPTAC; CPTAC-1275; -.
DR   CPTAC; CPTAC-1276; -.
DR   CPTAC; CPTAC-1751; -.
DR   CPTAC; CPTAC-5962; -.
DR   CPTAC; non-CPTAC-5439; -.
DR   CPTAC; non-CPTAC-5440; -.
DR   CPTAC; non-CPTAC-5713; -.
DR   CPTAC; non-CPTAC-5714; -.
DR   jPOST; P40763; -.
DR   MassIVE; P40763; -.
DR   PaxDb; 9606-ENSP00000264657; -.
DR   PeptideAtlas; P40763; -.
DR   ProteomicsDB; 55378; -. [P40763-1]
DR   ProteomicsDB; 55379; -. [P40763-2]
DR   Pumba; P40763; -.
DR   ABCD; P40763; 38 sequenced antibodies.
DR   Antibodypedia; 660; 2579 antibodies from 55 providers.
DR   CPTC; P40763; 2 antibodies.
DR   DNASU; 6774; -.
DR   Ensembl; ENST00000264657.10; ENSP00000264657.4; ENSG00000168610.17. [P40763-1]
DR   Ensembl; ENST00000404395.3; ENSP00000384943.3; ENSG00000168610.17. [P40763-2]
DR   Ensembl; ENST00000585517.5; ENSP00000467000.1; ENSG00000168610.17. [P40763-3]
DR   Ensembl; ENST00000588969.5; ENSP00000467985.1; ENSG00000168610.17. [P40763-1]
DR   Ensembl; ENST00000677030.1; ENSP00000503662.1; ENSG00000168610.17. [P40763-3]
DR   Ensembl; ENST00000677723.1; ENSP00000503574.1; ENSG00000168610.17. [P40763-2]
DR   Ensembl; ENST00000678044.1; ENSP00000503102.1; ENSG00000168610.17. [P40763-1]
DR   Ensembl; ENST00000678827.1; ENSP00000503634.1; ENSG00000168610.17. [P40763-3]
DR   Ensembl; ENST00000678906.1; ENSP00000504184.1; ENSG00000168610.17. [P40763-1]
DR   Ensembl; ENST00000678960.1; ENSP00000503181.1; ENSG00000168610.17. [P40763-1]
DR   Ensembl; ENST00000679014.1; ENSP00000503237.1; ENSG00000168610.17. [P40763-2]
DR   Ensembl; ENST00000715205.1; ENSP00000520412.1; ENSG00000168610.17. [P40763-1]
DR   GeneID; 6774; -.
DR   KEGG; hsa:6774; -.
DR   MANE-Select; ENST00000264657.10; ENSP00000264657.4; NM_139276.3; NP_644805.1.
DR   UCSC; uc002hzl.2; human. [P40763-1]
DR   AGR; HGNC:11364; -.
DR   CTD; 6774; -.
DR   DisGeNET; 6774; -.
DR   GeneCards; STAT3; -.
DR   GeneReviews; STAT3; -.
DR   HGNC; HGNC:11364; STAT3.
DR   HPA; ENSG00000168610; Low tissue specificity.
DR   MalaCards; STAT3; -.
DR   MIM; 102582; gene.
DR   MIM; 147060; phenotype.
DR   MIM; 615952; phenotype.
DR   OpenTargets; ENSG00000168610; -.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 2314; Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency.
DR   Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma.
DR   Orphanet; 512017; Chronic lymphoproliferative disorder of natural killer cells.
DR   Orphanet; 99885; Isolated permanent neonatal diabetes mellitus.
DR   Orphanet; 438159; STAT3-related early-onset multisystem autoimmune disease.
DR   Orphanet; 86872; T-cell large granular lymphocyte leukemia.
DR   VEuPathDB; HostDB:ENSG00000168610; -.
DR   eggNOG; KOG3667; Eukaryota.
DR   GeneTree; ENSGT01050000244905; -.
DR   HOGENOM; CLU_014189_3_0_1; -.
DR   InParanoid; P40763; -.
DR   OrthoDB; 19300at2759; -.
DR   PAN-GO; P40763; 9 GO annotations based on evolutionary models.
DR   PhylomeDB; P40763; -.
DR   PathwayCommons; P40763; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-111453; BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-198745; Signalling to STAT3.
DR   Reactome; R-HSA-201556; Signaling by ALK.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2586552; Signaling by Leptin.
DR   Reactome; R-HSA-2892247; POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8849474; PTK6 Activates STAT3.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8875791; MET activates STAT3.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-8985947; Interleukin-9 signaling.
DR   Reactome; R-HSA-9008059; Interleukin-37 signaling.
DR   Reactome; R-HSA-9020933; Interleukin-23 signaling.
DR   Reactome; R-HSA-9020956; Interleukin-27 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants.
DR   Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants.
DR   Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants.
DR   Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF).
DR   Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells.
DR   Reactome; R-HSA-9701898; STAT3 nuclear events downstream of ALK signaling.
DR   Reactome; R-HSA-9705462; Inactivation of CSF3 (G-CSF) signaling.
DR   Reactome; R-HSA-9707564; Cytoprotection by HMOX1.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   Reactome; R-HSA-9833482; PKR-mediated signaling.
DR   SignaLink; P40763; -.
DR   SIGNOR; P40763; -.
DR   BioGRID-ORCS; 6774; 40 hits in 1196 CRISPR screens.
DR   CD-CODE; 38EC0B30; Transcriptional condensate.
DR   CD-CODE; 804901D1; Nuclear speckle.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   ChiTaRS; STAT3; human.
DR   EvolutionaryTrace; P40763; -.
DR   GeneWiki; STAT3; -.
DR   GenomeRNAi; 6774; -.
DR   Pharos; P40763; Tchem.
DR   PRO; PR:P40763; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P40763; protein.
DR   Bgee; ENSG00000168610; Expressed in type B pancreatic cell and 211 other cell types or tissues.
DR   ExpressionAtlas; P40763; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IMP:BHF-UCL.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:ARUK-UCL.
DR   GO; GO:0031730; F:CCR5 chemokine receptor binding; IEA:Ensembl.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0106222; F:lncRNA binding; IDA:FlyBase.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IEA:Ensembl.
DR   GO; GO:0004879; F:nuclear receptor activity; IDA:BHF-UCL.
DR   GO; GO:0070878; F:primary miRNA binding; IPI:ARUK-UCL.
DR   GO; GO:0046983; F:protein dimerization activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0140311; F:protein sequestering activity; ISS:UniProt.
DR   GO; GO:0003723; F:RNA binding; IPI:ARUK-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0140610; F:RNA sequestering activity; IDA:ARUK-UCL.
DR   GO; GO:0035591; F:signaling adaptor activity; IPI:ARUK-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:Ensembl.
DR   GO; GO:0048708; P:astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IDA:UniProt.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IDA:UniProt.
DR   GO; GO:0097696; P:cell surface receptor signaling pathway via STAT; IMP:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0097398; P:cellular response to interleukin-17; IEA:Ensembl.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; NAS:UniProtKB.
DR   GO; GO:0006952; P:defense response; IBA:GO_Central.
DR   GO; GO:0042755; P:eating behavior; ISS:UniProtKB.
DR   GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0001754; P:eye photoreceptor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; IDA:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0140105; P:interleukin-10-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0038154; P:interleukin-11-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0035723; P:interleukin-15-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0038110; P:interleukin-2-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0038155; P:interleukin-23-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038113; P:interleukin-9-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0033210; P:leptin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0010507; P:negative regulation of autophagy; IDA:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; ISS:UniProt.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; ISS:UniProt.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; IEA:Ensembl.
DR   GO; GO:0010730; P:negative regulation of hydrogen peroxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:UniProt.
DR   GO; GO:0106015; P:negative regulation of inflammatory response to wounding; IDA:UniProt.
DR   GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl.
DR   GO; GO:2000635; P:negative regulation of primary miRNA processing; IMP:ARUK-UCL.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt.
DR   GO; GO:0016310; P:phosphorylation; ISS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:2001171; P:positive regulation of ATP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:ARUK-UCL.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IGI:ARUK-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; IGI:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:1902728; P:positive regulation of growth factor dependent skeletal muscle satellite cell proliferation; IEA:Ensembl.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IGI:ARUK-UCL.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; IGI:ARUK-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISS:ARUK-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IGI:ARUK-UCL.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISS:UniProtKB.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IDA:UniProt.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IGI:ARUK-UCL.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:BHF-UCL.
DR   GO; GO:0099527; P:postsynapse to nucleus signaling pathway; IEA:Ensembl.
DR   GO; GO:0006606; P:protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:0060019; P:radial glial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:1900037; P:regulation of cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0060259; P:regulation of feeding behavior; ISS:UniProtKB.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0044321; P:response to leptin; IDA:UniProtKB.
DR   GO; GO:0043434; P:response to peptide hormone; IBA:GO_Central.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0060221; P:retinal rod cell differentiation; IEA:Ensembl.
DR   GO; GO:0019953; P:sexual reproduction; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; ISS:UniProtKB.
DR   GO; GO:0072538; P:T-helper 17 type immune response; IDA:UniProtKB.
DR   GO; GO:0001659; P:temperature homeostasis; ISS:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IGI:ARUK-UCL.
DR   CDD; cd10374; SH2_STAT3; 1.
DR   CDD; cd16853; STAT3_CCD; 1.
DR   CDD; cd16847; STAT3_DBD; 1.
DR   FunFam; 1.10.238.10:FF:000012; Signal transducer and activator of transcription; 1.
DR   FunFam; 1.10.532.10:FF:000001; Signal transducer and activator of transcription; 1.
DR   FunFam; 1.20.1050.20:FF:000003; Signal transducer and activator of transcription; 1.
DR   FunFam; 3.30.505.10:FF:000003; Signal transducer and activator of transcription; 1.
DR   FunFam; 2.60.40.630:FF:000012; Signal transducer and activator of transcription 3; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 1.20.1050.20; STAT transcription factor, all-alpha domain; 1.
DR   Gene3D; 2.60.40.630; STAT transcription factor, DNA-binding domain; 1.
DR   Gene3D; 1.10.532.10; STAT transcription factor, N-terminal domain; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001217; STAT.
DR   InterPro; IPR035855; STAT3_SH2.
DR   InterPro; IPR048988; STAT_linker.
DR   InterPro; IPR036535; STAT_N_sf.
DR   InterPro; IPR013800; STAT_TF_alpha.
DR   InterPro; IPR015988; STAT_TF_coiled-coil.
DR   InterPro; IPR013801; STAT_TF_DNA-bd.
DR   InterPro; IPR012345; STAT_TF_DNA-bd_N.
DR   InterPro; IPR013799; STAT_TF_prot_interaction.
DR   PANTHER; PTHR11801; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF01017; STAT_alpha; 1.
DR   Pfam; PF02864; STAT_bind; 1.
DR   Pfam; PF02865; STAT_int; 1.
DR   Pfam; PF21354; STAT_linker; 1.
DR   SMART; SM00964; STAT_int; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   SUPFAM; SSF47655; STAT; 1.
DR   SUPFAM; SSF48092; Transcription factor STAT-4 N-domain; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   neXtProt; NX_P40763; -.
DR   PharmGKB; PA337; -.
DR   TreeFam; TF318648; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm;
KW   Diabetes mellitus; Disease variant; DNA-binding; Dwarfism;
KW   Host-virus interaction; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; SH2 domain; Transcription; Transcription regulation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   CHAIN           2..770
FT                   /note="Signal transducer and activator of transcription 3"
FT                   /id="PRO_0000182417"
FT   DOMAIN          580..670
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   MOTIF           150..162
FT                   /note="Essential for nuclear import"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   MOD_RES         49
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16285960,
FT                   ECO:0000269|PubMed:18782771"
FT   MOD_RES         87
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16285960,
FT                   ECO:0000269|PubMed:18782771, ECO:0000269|PubMed:28262505"
FT   MOD_RES         601
FT                   /note="Allysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         601
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         615
FT                   /note="Allysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         615
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         631
FT                   /note="Allysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         631
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         640
FT                   /note="Phosphotyrosine; by TYK2"
FT                   /evidence="ECO:0000269|PubMed:29162862"
FT   MOD_RES         685
FT                   /note="Allysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         685
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:15653507,
FT                   ECO:0000269|PubMed:28065600"
FT   MOD_RES         705
FT                   /note="Phosphotyrosine; by FER and PTK6"
FT                   /evidence="ECO:0000269|PubMed:12763138,
FT                   ECO:0000269|PubMed:16568091, ECO:0000269|PubMed:21135090,
FT                   ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:26293184,
FT                   ECO:0000269|PubMed:31899195, ECO:0000269|PubMed:32929201,
FT                   ECO:0007744|PubMed:15592455, ECO:0007744|PubMed:24275569"
FT   MOD_RES         707
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MOD_RES         714
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         727
FT                   /note="Phosphoserine; by DYRK2, NLK, NEK6, IRAK1, RPS6KA5,
FT                   ZIPK/DAPK3 and PKC/PRKCE"
FT                   /evidence="ECO:0000269|PubMed:12763138,
FT                   ECO:0000269|PubMed:15465816, ECO:0000269|PubMed:16219639,
FT                   ECO:0000269|PubMed:17875724, ECO:0000269|PubMed:18599021,
FT                   ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:26293184,
FT                   ECO:0000269|PubMed:31899195, ECO:0000269|PubMed:32797246,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         701
FT                   /note="Missing (in isoform Del-701)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010474"
FT   VAR_SEQ         716..722
FT                   /note="TTCSNTI -> FIDAVWK (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_055918"
FT   VAR_SEQ         723..770
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_055919"
FT   VARIANT         32
FT                   /note="Q -> K (in dbSNP:rs1803125)"
FT                   /id="VAR_018683"
FT   VARIANT         70
FT                   /note="R -> H (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089785"
FT   VARIANT         103
FT                   /note="R -> W (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089786"
FT   VARIANT         107
FT                   /note="R -> W (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089787"
FT   VARIANT         143
FT                   /note="M -> I (in dbSNP:rs17878478)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_018679"
FT   VARIANT         152
FT                   /note="R -> W (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089788"
FT   VARIANT         162
FT                   /note="M -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089789"
FT   VARIANT         166
FT                   /note="E -> D (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089790"
FT   VARIANT         166
FT                   /note="E -> K (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089791"
FT   VARIANT         174
FT                   /note="F -> S (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089792"
FT   VARIANT         218
FT                   /note="V -> A (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089793"
FT   VARIANT         260
FT                   /note="L -> P (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089794"
FT   VARIANT         278
FT                   /note="R -> C (in ADMIO1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089795"
FT   VARIANT         278
FT                   /note="R -> H (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:28579554,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089796"
FT   VARIANT         302
FT                   /note="R -> Q (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089797"
FT   VARIANT         325
FT                   /note="R -> W (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089798"
FT   VARIANT         330
FT                   /note="P -> S (in ADMIO1; increases transcriptional
FT                   activity; increases binding to ISL1 promoter region;
FT                   decreases glucose stimulated insulin secretion)"
FT                   /evidence="ECO:0000269|PubMed:28073828"
FT                   /id="VAR_078445"
FT   VARIANT         331
FT                   /note="M -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089799"
FT   VARIANT         344
FT                   /note="Q -> H (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089800"
FT   VARIANT         353
FT                   /note="V -> F (in ADMIO1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089801"
FT   VARIANT         357
FT                   /note="E -> K (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation; increased
FT                   phosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:38404237"
FT                   /id="VAR_089802"
FT   VARIANT         361
FT                   /note="Q -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089803"
FT   VARIANT         382
FT                   /note="R -> L (in HIES1; dbSNP:rs113994136)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037365"
FT   VARIANT         382
FT                   /note="R -> Q (in HIES1; loss of function;
FT                   dbSNP:rs113994136)"
FT                   /evidence="ECO:0000269|PubMed:17676033,
FT                   ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037366"
FT   VARIANT         382
FT                   /note="R -> W (in HIES1; loss of function; reduced
FT                   DNA-binding ability; dbSNP:rs113994135)"
FT                   /evidence="ECO:0000269|PubMed:17676033,
FT                   ECO:0000269|PubMed:17881745, ECO:0000269|PubMed:26293184"
FT                   /id="VAR_037367"
FT   VARIANT         384
FT                   /note="F -> L (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037368"
FT   VARIANT         384
FT                   /note="F -> S (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037369"
FT   VARIANT         387
FT                   /note="L -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089804"
FT   VARIANT         389
FT                   /note="T -> A (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089805"
FT   VARIANT         389
FT                   /note="T -> I (in HIES1; likely pathogenic; loss of
FT                   transcriptional activity; dbSNP:rs397514766)"
FT                   /evidence="ECO:0000269|PubMed:17676033,
FT                   ECO:0000269|PubMed:23342295"
FT                   /id="VAR_037370"
FT   VARIANT         389
FT                   /note="T -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089806"
FT   VARIANT         389
FT                   /note="T -> S (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089807"
FT   VARIANT         392
FT                   /note="K -> R (in ADMIO1; results in increased
FT                   transcriptional activation; dbSNP:rs587777648)"
FT                   /evidence="ECO:0000269|PubMed:25038750,
FT                   ECO:0000269|PubMed:28579554"
FT                   /id="VAR_071885"
FT   VARIANT         394
FT                   /note="M -> T (in ADMIO1; pathogenic; results in increased
FT                   transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:28579554,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089808"
FT   VARIANT         395
FT                   /note="N -> Y (in HIES1; uncertain significance; reduced
FT                   DNA-binding ability)"
FT                   /evidence="ECO:0000269|PubMed:26293184"
FT                   /id="VAR_075414"
FT   VARIANT         408
FT                   /note="F -> L (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089809"
FT   VARIANT         415
FT                   /note="E -> G (in ADMIO1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089810"
FT   VARIANT         415
FT                   /note="E -> K (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089811"
FT   VARIANT         415
FT                   /note="E -> Q (in ADMIO1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089812"
FT   VARIANT         419
FT                   /note="G -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089813"
FT   VARIANT         420
FT                   /note="N -> K (in ADMIO1; likely pathogenic; results in
FT                   slightly increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089814"
FT   VARIANT         421
FT                   /note="G -> R (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089815"
FT   VARIANT         422
FT                   /note="G -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089816"
FT   VARIANT         423
FT                   /note="R -> Q (in HIES1; dbSNP:rs113994137)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037371"
FT   VARIANT         425
FT                   /note="N -> Y (in HIES1; uncertain significance; reduced
FT                   DNA-binding ability)"
FT                   /evidence="ECO:0000269|PubMed:26293184"
FT                   /id="VAR_075415"
FT   VARIANT         437
FT                   /note="H -> Y (in HIES1; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:17676033"
FT                   /id="VAR_037372"
FT   VARIANT         443
FT                   /note="T -> I (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089817"
FT   VARIANT         447
FT                   /note="H -> D (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089818"
FT   VARIANT         448
FT                   /note="Q -> E (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089819"
FT   VARIANT         463
FT                   /note="Missing (in HIES1; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:17676033,
FT                   ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037373"
FT   VARIANT         506
FT                   /note="E -> K (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089820"
FT   VARIANT         546
FT                   /note="W -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089821"
FT   VARIANT         561
FT                   /note="F -> Y (in dbSNP:rs1064116)"
FT                   /evidence="ECO:0000269|PubMed:7512451"
FT                   /id="VAR_037374"
FT   VARIANT         611
FT                   /note="S -> N (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037375"
FT   VARIANT         621
FT                   /note="F -> V (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037376"
FT   VARIANT         622
FT                   /note="T -> I (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037377"
FT   VARIANT         637
FT                   /note="V -> L (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037378"
FT   VARIANT         637
FT                   /note="V -> M (in HIES1; reduced DNA-binding ability;
FT                   dbSNP:rs113994139)"
FT                   /evidence="ECO:0000269|PubMed:17881745,
FT                   ECO:0000269|PubMed:26293184"
FT                   /id="VAR_037379"
FT   VARIANT         640
FT                   /note="Y -> F (in ADMIO1; likely pathogenic;
FT                   gain-of-function variant resulting in increased
FT                   transcriptional activation following IFN and LIF
FT                   stimulation; increased phosphorylation at Y-705 and
FT                   translocation to the nucleus)"
FT                   /evidence="ECO:0000269|PubMed:29162862,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089822"
FT   VARIANT         643
FT                   /note="Q -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089823"
FT   VARIANT         644
FT                   /note="Missing (in HIES1)"
FT                   /evidence="ECO:0000269|PubMed:17881745"
FT                   /id="VAR_037380"
FT   VARIANT         646
FT                   /note="N -> K (in ADMIO1; dbSNP:rs587777649)"
FT                   /evidence="ECO:0000269|PubMed:25038750,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_071886"
FT   VARIANT         657
FT                   /note="Y -> C (in HIES1; reduced DNA-binding ability;
FT                   dbSNP:rs193922721)"
FT                   /evidence="ECO:0000269|PubMed:17881745,
FT                   ECO:0000269|PubMed:26293184"
FT                   /id="VAR_037381"
FT   VARIANT         658
FT                   /note="K -> N (in ADMIO1; dbSNP:rs587777650)"
FT                   /evidence="ECO:0000269|PubMed:25038750"
FT                   /id="VAR_071887"
FT   VARIANT         658
FT                   /note="K -> R (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089824"
FT   VARIANT         663
FT                   /note="T -> I (in ADMIO1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:25359994,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089825"
FT   VARIANT         664
FT                   /note="N -> Y (in ADMIO1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089826"
FT   VARIANT         703
FT                   /note="A -> T (in ADMIO1; likely pathogenic; results in
FT                   increased transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:25359994"
FT                   /id="VAR_089827"
FT   VARIANT         715
FT                   /note="P -> L (in ADMIO1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:28253502,
FT                   ECO:0000269|PubMed:36228738"
FT                   /id="VAR_089828"
FT   VARIANT         716
FT                   /note="T -> M (in ADMIO1; pathogenic; results in increased
FT                   transcriptional activation; dbSNP:rs869312892)"
FT                   /evidence="ECO:0000269|PubMed:25038750,
FT                   ECO:0000269|PubMed:25359994, ECO:0000269|PubMed:36228738"
FT                   /id="VAR_071888"
FT   MUTAGEN         49
FT                   /note="K->Q: Mimics acetylation; increased interaction with
FT                   EP300; when associated with Q-87."
FT                   /evidence="ECO:0000269|PubMed:18782771"
FT   MUTAGEN         49
FT                   /note="K->R: Decreased transcription activator activity and
FT                   interaction with EP300; when associated with R-87."
FT                   /evidence="ECO:0000269|PubMed:16285960,
FT                   ECO:0000269|PubMed:18782771"
FT   MUTAGEN         87
FT                   /note="K->Q: Mimics acetylation; increased interaction with
FT                   EP300; when associated with Q-49."
FT                   /evidence="ECO:0000269|PubMed:18782771"
FT   MUTAGEN         87
FT                   /note="K->R: Decreased transcription activator activity and
FT                   interaction with EP300; when associated with R-49."
FT                   /evidence="ECO:0000269|PubMed:16285960,
FT                   ECO:0000269|PubMed:18782771"
FT   MUTAGEN         434..435
FT                   /note="EE->AA: Inhibits leptin-mediated transactivation of
FT                   CCND1 promoter. No effect on interaction with INPP5F."
FT                   /evidence="ECO:0000269|PubMed:17344214,
FT                   ECO:0000269|PubMed:25476455"
FT   MUTAGEN         685
FT                   /note="K->R: Decreased acetylation by EP300/p300, leading
FT                   to impaired homodimerization and activation."
FT                   /evidence="ECO:0000269|PubMed:15653507"
FT   MUTAGEN         705
FT                   /note="Y->F: Inhibits leptin-mediated transactivation of
FT                   CCND1 promoter. Abolished phosphorylation by isoform M2 of
FT                   PKM (PKM2)."
FT                   /evidence="ECO:0000269|PubMed:17344214,
FT                   ECO:0000269|PubMed:22306293"
FT   CONFLICT        133
FT                   /note="T -> A (in Ref. 4; BAF84622)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288
FT                   /note="Q -> H (in Ref. 1; AAA58374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        460
FT                   /note="P -> S (in Ref. 1; AAA58374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        548
FT                   /note="K -> N (in Ref. 1; AAA58374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        652
FT                   /note="E -> V (in Ref. 4; BAF84622)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        667
FT                   /note="V -> L (in Ref. 1; AAA58374)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        730
FT                   /note="T -> A (in Ref. 1; AAA58374)"
FT                   /evidence="ECO:0000305"
FT   HELIX           139..177
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           194..237
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           239..251
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           261..290
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           297..320
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          321..328
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          338..340
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          345..353
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           356..358
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   TURN            359..361
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          363..368
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          373..376
FT                   /evidence="ECO:0007829|PDB:6QHD"
FT   STRAND          384..388
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          391..393
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   TURN            398..401
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          404..415
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           432..434
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          439..447
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          450..457
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          461..466
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           467..469
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           470..483
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   TURN            490..494
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           501..513
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          514..517
FT                   /evidence="ECO:0007829|PDB:6TLC"
FT   HELIX           522..533
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           546..549
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          557..559
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           561..574
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           577..582
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           591..600
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          605..610
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          619..626
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   STRAND          632..636
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           642..645
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           650..656
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   TURN            674..676
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           679..683
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   HELIX           684..686
FT                   /evidence="ECO:0007829|PDB:6NJS"
FT   MOD_RES         P40763-2:704
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455,
FT                   ECO:0007744|PubMed:24275569"
SQ   SEQUENCE   770 AA;  88068 MW;  6C00632211C8012D CRC64;
     MAQWNQLQQL DTRYLEQLHQ LYSDSFPMEL RQFLAPWIES QDWAYAASKE SHATLVFHNL
     LGEIDQQYSR FLQESNVLYQ HNLRRIKQFL QSRYLEKPME IARIVARCLW EESRLLQTAA
     TAAQQGGQAN HPTAAVVTEK QQMLEQHLQD VRKRVQDLEQ KMKVVENLQD DFDFNYKTLK
     SQGDMQDLNG NNQSVTRQKM QQLEQMLTAL DQMRRSIVSE LAGLLSAMEY VQKTLTDEEL
     ADWKRRQQIA CIGGPPNICL DRLENWITSL AESQLQTRQQ IKKLEELQQK VSYKGDPIVQ
     HRPMLEERIV ELFRNLMKSA FVVERQPCMP MHPDRPLVIK TGVQFTTKVR LLVKFPELNY
     QLKIKVCIDK DSGDVAALRG SRKFNILGTN TKVMNMEESN NGSLSAEFKH LTLREQRCGN
     GGRANCDASL IVTEELHLIT FETEVYHQGL KIDLETHSLP VVVISNICQM PNAWASILWY
     NMLTNNPKNV NFFTKPPIGT WDQVAEVLSW QFSSTTKRGL SIEQLTTLAE KLLGPGVNYS
     GCQITWAKFC KENMAGKGFS FWVWLDNIID LVKKYILALW NEGYIMGFIS KERERAILST
     KPPGTFLLRF SESSKEGGVT FTWVEKDISG KTQIQSVEPY TKQQLNNMSF AEIIMGYKIM
     DATNILVSPL VYLYPDIPKE EAFGKYCRPE SQEHPEADPG SAAPYLKTKF ICVTPTTCSN
     TIDLPMSPRT LDSLMQFGNN GEGAEPSAGG QFESLTFDME LTSECATSPM
//
